PMG
MDCO

ProVise Management Group’s Medicines Co MDCO Stock Holding History

ProVise Management Group’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-7,828
Closed -$241K – 344
2013
Q2 		$241K Buy
+7,828
New +$262K 0.07% 275

Other funds holding MDCO

SAC
Smith Affiliated Capital New York $86.5B AUM 5.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ProVise Management Group's MDCO Position: Q3 2013 in Review

ProVise Management Group sold out of Medicines Co (MDCO) in Q3 2013, closing a stake of 7,828 shares — an estimated $241K sold.

ProVise Management Group first reported a position in MDCO in Q2 2013 and held it in 1 quarter. The position peaked at $241K in Q2 2013. 172 funds tracked by Wall St. Rank hold MDCO as of Q3 2013.

  • ProVise Management Group reported no remaining Medicines Co position as of Q3 2013 after selling out during the quarter.
  • ProVise Management Group sold 7,828 Medicines Co shares in Q3 2013, an estimated $241K.
  • ProVise Management Group first reported a position in Medicines Co in Q2 2013 and held it in 1 quarter.
  • ProVise Management Group's Medicines Co position peaked at $241K in Q2 2013.
  • 172 funds tracked by Wall St. Rank held Medicines Co as of Q3 2013.

Based on ProVise Management Group's 13F filing for Q3 2013, filed 12 Nov 2013.